Ernexa Therapeutics Inc (ERNA)

NASDAQ

Currency in USD

ERNA Pro Research

0.194

+0.003(+1.57%)

Closed·22/04

After Hours

0.1940.000(-0.15%)

·22/04

Fair Value

Unlock Value

Day's Range

0.192

0.200

52 wk Range

0.184

4.019

ERNA Income Statement

Assess the Ernexa Therapeutics income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the ERNA net worth.

Period Ending:

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

0.07

0.58

Total Revenues Growth

aa.aa

+755.88%

Cost Of Revenues

aa.aa

0.24

0.1

Gross Profit

aa.aa

-0.17

0.49

Gross Profit Growth

aa.aa

+389.29%

Gross Profit Margin %

aa.aa

-247.06%

83.51%

Other Operating Expenses, Total

aa.aa

20.51

17.74

9.32

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-24.68%	-13.51%	-47.46%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5.73	4.6	4.16
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	14.77	13.13	5.16
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-

Operating Income

aa.aa

-20.68

-17.25

-9.32

Operating Income Growth

aa.aa

+24.06%

+16.57%

+45.98%

EBIT Margin %

aa.aa

-30,404.41%

-2,963.92%

Net Interest Expenses

aa.aa

-0.48

-6.5

0.06

Net Interest Expenses Growth

aa.aa

-1,486.67%

-1,266.18%

+100.86%

Interest Expense, Total

aa.aa

-0.61

-6.75

-0.03

Interest And Investment Income

aa.aa

0.14

0.25

0.08

Other Non Operating Expenses, Total

aa.aa

-0.12

-0.98

-5.63

EBT, Excl. Unusual Items

aa.aa

-21.27

-24.73

-14.89

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

-0.34

-19.78

0.77

EBT, Incl. Unusual Items

aa.aa

-21.67

-44.51

-14.13

EBT, Incl. Unusual Items Growth

aa.aa

+11.67%

-105.39%

+68.26%

EBT, Incl. Unusual Items Margin

aa.aa

-31,869.12%

-7,647.59%

Income Tax Expense

aa.aa

-0

0.03

-0.05

Net Income to Company

aa.aa

-21.67

-44.54

-14.08

Minority Interest

aa.aa

Net Income

aa.aa

-21.67

-44.54

-14.08

Net Income Growth

aa.aa

+11.84%

-105.55%

+68.38%

Net Income Margin %

aa.aa

-31,864.71%

-7,652.75%

Preferred Dividend and Other Adjustments

aa.aa

0.02

Net Income to Common Excl. Extra Items

aa.aa

-21.68

-44.56

-14.1

Basic EPS - Continuing Operations

aa.aa

-61.21

-48.96

-2.24

Basic EPS - Continuing Operations Growth

aa.aa

+49.38%

+20.01%

+95.43%

Diluted EPS - Continuing Operations

aa.aa

-61.21

-48.96

-2.24

Diluted EPS - Continuing Operations Growth

aa.aa

+49.38%

+20.01%

+95.43%

Basic Weighted Average Shares Outstanding

aa.aa

0.35

0.91

6.31

Diluted Weighted Average Shares Outstanding

aa.aa

0.35

0.91

6.31

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-20.59

-17.11

-9.25

EBITDA Growth

aa.aa

+23.92%

+16.9%

+45.92%

EBITDA Margin %

aa.aa

-30,280.88%

-2,940.03%

EBIT

aa.aa

-20.68

-17.25

-9.32

* In Millions of USD (except for per share items)

FAQ

What was Ernexa Therapeutics’s net income for the year?

For the full year, Ernexa Therapeutics reported net income of -14.084 million USD.

How much net income did Ernexa Therapeutics post in the last quarter?

In the most recent quarter, Ernexa Therapeutics (ERNA) posted net income of -1.502 million USD.

What was Ernexa Therapeutics’s annual operating income?

For the full year, Ernexa Therapeutics (ERNA) reported operating income of -9.319 million USD.

What was Ernexa Therapeutics’s operating income last quarter?

Quarterly operating income was -2.094 million USD.

What was Ernexa Therapeutics’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -2.081 million USD.

What was the quarter-over-quarter change in EBITDA for Ernexa Therapeutics?

EBITDA changed by -5.314% million USD compared to the last quarter.

S&P/TSX

33,955.11

+146.81

+0.43%

S&P/TSX 60

1,976.73

+4.38

+0.22%

US 30

49,177.50

-313.3

-0.63%

US 500

7,106.40

-31.5

-0.44%

S&P 500 VIX

19.62

+0.70

+3.70%

DAX

24,085.50

-124.73

-0.52%

Dollar Index

98.622

+0.210

+0.21%

Market Movers

Name	Last	Chg. %	Vol.
Rogers Communications	51.21	+13.55%	6.58M
Canadian Natural	61.11	+0.92%	6.21M
Enbridge	70.86	-0.17%	4.05M
Bank of Nova Scotia	102.77	-0.97%	3.56M
RBC	241.26	-0.64%	2.65M
Toronto Dominion Bank	142.93	-0.82%	2.26M
Bank of Montreal	206.37	-0.42%	1.17M

Name	Last	Chg. %	Vol.
Nirvana Life Sciences	0.04	+700.00%	11.33K
PeakBirch Logic	0.030	+500.00%	1.32K
New Leaf Ventures	0.05	+400.00%	666.82K
Glass House Brands	0.15	+200.00%	85.10K
1933 Industries	0.01	+200.00%	30.00K
Mayfair Acquisition	0.05	+150.00%	3.00K
Irwin Naturals	0.30	+150.00%	3.24K

Name	Last	Chg. %	Vol.
Rivalry	0.01	-100.00%	50.90K
Metamaterial	0.25	-92.86%	0.00
New Frontier Ventures	0.030	-68.42%	13.00K
CordovaCann	0.0150	-57.14%	22.00K
Molecule Holdings	0.005	-50.00%	20.11K
Champion Electric	0.005	-50.00%	254.50K
Seasif Exploration	0.0050	-50.00%	850.10K

Trending Stocks

Name	Last	Chg. %	Vol.
Canopy Growth	1.890	+21.15%	13.04M
Air Canada	18.29	-2.82%	3.64M
Hut 8	110.360	+5.43%	1.11M
Celestica Inc.	549.77	-0.32%	418.46K
TELUS	16.82	0.00%	5.61M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aa Aaaaaaaaaaaa	5.26	+61.02%	8.47
Aaaaa Aaa	43.24	+51.02%	65.30
Aaaaaa Aaaaaa	104.61	+49.29%	156.17
Aaa Aaaaaaaaaa	22.96	+42.56%	32.73
Aaaaaa	6.65	+41.97%	9.44
A A Aa Aaa	258.13	+40.34%	362.26
Aaaaaa Aa A	10.82	+40.07%	15.16

Name	Last	Upside	Fair Value
Aa Aaaaaaaaaaaa	5.26	+61.02%	8.47
Aaaaa Aaa	43.24	+51.02%	65.30
Aaaaaa Aaaaaa	104.61	+49.29%	156.17
Aaa Aaaaaaaaaa	22.96	+42.56%	32.73
Aaaaaa	6.65	+41.97%	9.44
A A Aa Aaa	258.13	+40.34%	362.26
Aaaaaa Aa A	10.82	+40.07%	15.16

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Ernexa Therapeutics Inc (ERNA)

ERNA Income Statement

FAQ

What was Ernexa Therapeutics’s net income for the year?

How much net income did Ernexa Therapeutics post in the last quarter?

What was Ernexa Therapeutics’s annual operating income?

What was Ernexa Therapeutics’s operating income last quarter?

What was Ernexa Therapeutics’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Ernexa Therapeutics?

Trending Stocks